Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation

Annals of Oncology

Volumn 19, Issue 5, 2008, Pages 927-934

  Mourad, J J ^a   des Guetz, G ^a   Debbabi, H ^b   Levy, B I ^b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Angiogenesis; Capillary rarefaction; Endothelial function; Hypertension; Microcirculation

Indexed keywords

ACETYLCHOLINE DERIVATIVE; BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; CAPECITABINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PILOCARPINE; VASCULOTROPIN;

ADULT; AGED; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; CAPILLARY DENSITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FEMALE; FINGER; HUMAN; HYPERTENSION; IONTOPHORESIS; LASER DOPPLER FLOWMETRY; MALE; METASTASIS; MICROCIRCULATION; MICROSCOPY; MICROVASCULATURE; PRIORITY JOURNAL; SKIN CAPILLARY; SYSTOLIC BLOOD PRESSURE; VASCULAR ENDOTHELIUM; VASODILATATION; VIDEORECORDING;

ADENOCARCINOMA; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD PRESSURE; CAPILLARIES; CHOLINERGIC AGENTS; COLORECTAL NEOPLASMS; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; FEMALE; FINGERS; FOREARM; HUMANS; HYPERTENSION; IONTOPHORESIS; LASER-DOPPLER FLOWMETRY; MALE; MICROCIRCULATION; MICROSCOPY, VIDEO; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PILOCARPINE; VASODILATION;

EID: 43049085201     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm550     Document Type: Article

References (45)

1. Sica DA. Angiogenesis inhibitors and hypertension: An emerging issue. J Clin Oncol 2006; 24: 1329-1330.
2. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody for metastatic renal cancer, N Engl J Med 2003; 349: 427-434.
3. Zakarija A, Soff G. Update on angiogenesis inhibitors: Curr Opin Oncol 2005; 17: 578-583.
4. Sane DC, Anton L, Brosnihan B. Angiogenic growth factors and hypertension. Angiogenesis 2004; 7: 193-201.
5. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2341.
6. Miller KD; Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792-799.
7. Thomas AL, Morgan B, Drevs J et al. Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK222584. Semin Oncol 2003; 30 (Suppl 6): 32-38.
8. Fiedler W, Serve H, Dohner H et al. A phase I study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005; 105: 986-993.
9. Zhu X, Wu S, Dahut WL et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007; 49: 186-193.
10. Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 2006; 63: 1475-1478.
11. Ozcan C, Wong SJ, Had P. Reversible posterior leukoencehallopathy syndrome and bevacizumab. N Engl J Med 2006; 354: 980-982.
12. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy-for cancer. Br J Cancer 2007; 96: 1788-1795.
13. Veronese ML, Mosenkis A, Flaherty KT et al. Mechanisms of hypertension associated with BAY 43-9006 treatment. J Clin Oncoll 2006; 24: 1363-1369.
14. Mir O, Mouthon L, Alexandre J et al. Bevacizumab-induced cardiovascular events: A consequence of cholesterol emboli syndrome? J Natl Cancer Inst 2007; 99: 85-86.
15. Olsson AK, Dimberg A, Kreuger J et al. VEGF receptor signaling in control of vascular function. Nat Rev Mol Cell Biol 2006; 7: 359-371.
16. Brunner H, Cockcroft JR, Deanfield J et al. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working-Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23: 233-246.
17. Levy BI, Ambrosio G, Pries AR et al. Microcirculation In hypertension: A new target for treatment? Circulation 2001; 104: 735-740.
18. Prewitt RL, Hashimoto H, Stacy DL. Structural and functional rarefaction of microvessels in hypertension. In Lee R (ed): Blood Vessel Changes in Hypertension: Structure and Function. Boca Raton, FL: CRC Press 1990; 71-90.
19. Shore AG. Capillaroscopy and the measurement of capillary pressure. Br J Clin Pharmacol 2000; 50: 501-513.
20. Debbabi H, Uzan L, Mourad JJ et al. Increased skin capillary density in treated essential hypertensive patients. Am J Hypertens 2006; 19: 477-483.
21. Semé EH, Stehouwer CDA, Ter Maaten JC et al. Microvascular function relates to insulin sensitivity and blood pressure in normal subjects, Circulation 1999; 99: 896-902.
22. Noon JP, Walker BR, Hand MF et al. Studies with iontophoretic administration of drugs to human dermal vessels in vivo: Cholinergic vasodilatation is mediated by dilator prostanoids rather than nitric oxide. Br J Clin Pharmacol 1998; 45: 545-550.
23. Henry TD, Annex BH, McKendall GR et al. The VIVA trial: Vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003; 107: 1359-1365.
24. Carmeliet P. Manipulating angiogenesis in medicine. J Intern Med 2004; 255: 538-561.
25. You D, Waeckel L, Ebrahimian TG et al. Increase in vascular permeability and vasodilation are critical for proangiogenic effects of stem cell therapy. Circulation 2006; 114: 328-338.
26. Feihl F, Liaudet L, Waeber B et al. Hypertension: A disease of the microcirculation? Hypertension 2006; 48: 1012-1017.
27. Clark JW, Eder JP, Ryan D et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005; 11: 5472-5480.
28. le Noble JL, Tangelder GJ, Slaaf DW et al. A functional morphometric study of the cremaster muscle microcirculation in young spontaneously hypertensive rats. J Hypertens 1990; 8: 741-748.
29. Mourad JJ, Laville M. Is hypertension a tissue perfusion disorder? Implications for renal and myocardial perfusion. J Hypertens (Suppl) 2006; 24: S10-S16.
30. Pattl PN, Stearns R. Mechanism of vascular relaxation by cholinomimetic drugs with special reference to pilocarpine and arecoline. J Ocul Pharmacol Ther 2002; 18: 25-34.
31. Papapetropoulos A, Garcia-Cardena G, Madri JA et al. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997; 100: 3131-3139.
32. Murohara T, Asahara T, Silver M et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 1998; 101: 2567-2578.
33. Gratton JP, Lin MI, Yu J et al. Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell. 2003; 4: 31-39.
34. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006; 6: 521-534.
35. Lala PK, Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol 2001; 2: 149-156.
36. Ziche M, Morbidelli L, Choudhuri R et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997; 99: 2625-2634.
37. Tamarat R, Silvestre JS, Kubis N et al. Endothelial nitric oxide synthase lies downstream from angiotensin II-induced angiogenesis in ischemic hindlimb. Hypertension 2002: 39: 830-835.
38. Fukumura D, Gohongi T, Kadambi A et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci U S A 2001; 98: 2604-2609.
39. Steeghs N, Hovens MM, Rabelink AJ et al. VEGFR2 blockade in patients with solid tumors: Mechanism of hypertension and effects an vascular function. J Clin Oncol Part I 2006; 24 (18 Suppl): (Abstr 3037).
40. Rossig L, Haendeler J, Hermann C et al. Nitric oxide down-regulates MKP-3 mRNA levels: Involvement in endothelial cell protection from apoptosis. J Biol Chem 2000; 275: 25502-25507.
41. Ying L, Hofseth LJ. An emerging role for endothelial nitric oxide synthase in chronic inflammation and cancer. Cancer Res 2007; 67: 1407-1410.
42. Baffert F, Le T, Sennino B et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol 2006; 290: H547-H559.
43. Meeson AP, Argilla M, Ko K et al. VEGF deprivation-induced apoptosis is a component of programmed capillary regression. Development 1999; 126: 1407-1415.
44. Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of sunitinib activity. Ann Oncol 2007; 18: 1117.
45. Maitland ML, Moshier K, Imperial J et al. Blood pressure (BP) as a biomarker for sorafenib (S), an inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway. J Clin Oncol 2006; 24: Part I (Abstr 2035).